Abstract
Summary: Postimplantation syndrome (PIS) following endovascular aortic aneurysm repair (EVAR) is a poorly understood phenomenon occurring in the early post-operative course. The underlying aetiology, risk factors, clinical sequalae, and treatment options, are largely unknown. The lack of any standardised diagnostic criteria limits current research in this field. The MEDLINE database was interrogated using a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) search strategy. Five search terms were used; “postimplantation syndrome” AND “aneurysm”, AND “infection”, AND “complications”, AND “biomarkers”, AND “outcomes”. 19 studies were included in the review process, reporting a 17.4%–39.0% incidence of PIS. IL-6 was the most commonly elevated biomarker in PIS vs. non-PIS patients. There was a higher incidence of PIS in patients who received polyester rather than expanded-polytetrafluoroethylene (ePTFE) grafts. There was a lower rate of type 2 endoleaks observed in patients who developed PIS. Early major adverse cardiovascular events (MACE) were higher in PIS patients, however there were no studies reporting long-term MACE. Length of stay was higher in PIS patients. Current data support the role of IL-6 as being key to the development of PIS following EVAR. Further work describing the effect that PIS has on long-term clinical outcomes is needed. Lack of standardised diagnostic criteria limit the reporting of PIS between centres, the criteria proposed by this review may resolve this.
References
1 . Suggested standards for reporting on arterial aneurysms. Subcommittee on Reporting Standards for Arterial Aneurysms, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery and North American Chapter, International Society for Cardiovascular Surgery. J Vasc Surg. 1991;13(3):452–8.
2 . Thoracic and abdominal aortic aneurysms. Circulation. 2005;111(6):816–28.
3 . Multicentre aneurysm screening study (MASS): Cost effectiveness analysis of screening for abdominal aortic aneurysms based on four year results from randomised controlled trial. BMJ. 2002;325(7373):1135.
4 . Screening for abdominal aortic aneurysm. Cochrane Database of Systematic Reviews. 2007;(2):CD002945.
5 . Guidelines for the treatment of abdominal aortic aneurysms: Report of a subcommittee of the Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. J Vasc Surg. 2003;37(5):1106–17.
6 . Controlling the expansion of abdominal aortic aneurysms. Br J Surg. 2003;90(8):897–8.
7 . Epidemiology of aortic aneurysm repair in the United States from 2000 to 2010. J Vasc Surg. 2014;59(6):1512–7.
8 . Transfemoral intraluminal graft implantation for abdominal aortic aneurysms. Ann Vasc Surg. 1991;5(6):491–9.
9 . Open and endovascular management of aortic aneurysms. Circ Res. 2019;124(4):647–61.
10 . Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19621072
11 Higgins JGreen S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration; 2011.
12 Preoperative methylprednisolone enhances recovery after endovascular aortic repair: A randomized, double-blind, placebo-controlled clinical trial. Ann Surg. 2014;260(3):540–9.
13 Post-implantation syndrome following endovascular abdominal aortic aneurysm repair: preliminary data. Interact Cardiovasc Thorac Surg. 2011;12(4):609–14.
14 Prospective evaluation of postimplantation syndrome evolution on patient outcomes after endovascular aneurysm repair for abdominal aortic aneurysm. J Vasc Surg. 2016;63(5).
15 Volume of new-onset thrombus is associated with the development of postimplantation syndrome after endovascular aneurysm repair. J Vasc Surg. 2014;60(5):1140–5.
16 . The role of procalcitonin in postimplantation syndrome after EVAR: a pilot study. Ann Vasc Surg. 2014;28(4):866–73.
17 Does a postimplantation syndrome following endovascular treatment of aortic aneurysms exist? Vasc Surg. 2001;35(1):23–9.
18 . Volume of mural thrombus plays a role in the elevation of inflammatory markers after endovascular aortic repair. J Cardiothorac Surg. 2018;13(1):27.
19 New predictors of aneurysm sac behavior after endovascular aortic aneurysm repair. Eur Radiol. 2019;29(12):6591–9.
20 Stent graft composition plays a material role in the postimplantation syndrome. J Vasc Surg. 2012;56(6):1503–9.
21 The impact of endograft type on inflammatory response after endovascular treatment of abdominal aortic aneurysm. J Vasc Surg. 2013;57(3):668–77.
22 Postimplantation syndrome after endovascular aortic repair using the anacondaTM endograft. Ann Vasc Surg. 2014;28(6):1409–15.
23 . The impact of stent graft material on the inflammatory response after EVAR. Vasc Endovascular Surg. 2015;49(3–4):79–83.
24 . Polyester grafts are a risk factor for postimplantation syndrome after abdominal endovascular aneurysm repair: retrospective analysis for polyester graft, Excluder®, and Endologix Powerlink®/AFX®. Ann Vasc Dis. 2018;11(4):520–4.
25 Effects of postimplantation systemic inflammatory response on long-term clinical outcomes after endovascular aneurysm repair of an abdominal aortic aneurysm. Med (United States). 2016;95(32).
26 Prospective evaluation of post-implantation inflammatory response after EVAR for AAA: Influence on patients’ 30 day outcome. Eur J Vasc Endovasc Surg. 2015;49(2):175–83.
27 . Il-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10).
28 . Tocilizumab. MAbs. 2009;1(5):432–8.
29 . Human endothelial cells produce IL-6. Lack of responses to exogenous IL-6. Ann N Y Acad Sci. 1989;557:374–85.;discussion 386–7.
30 Interleukin-6 production by endothelial cells via stimulation of protease-activated receptors is amplified by endotoxin and tumor necrosis factor-α. J Interf Cytokine Res. 2001;21(4):231–40.
31 Interleukin-6 gene expression in human endothelial cells: RNA start sites, multiple IL-6 proteins and inhibition of proliferation. Biochem Biophys Res Commun. 1989;159(3):991–8.
32 IL-1 stimulates IL-6 production in endothelial cells. J Immunol. 1989;142(2):549–53.
33 . Avaliação dos níveis séricos de interleucina-6 e interleucina-10 nos pacientes submetidos à colecistectomia laparoscópica versus convencional. Rev Col Bras Cir. 2012;39(1):33–40.
34 Elevation of circulating interleukin 6 after surgery: factors influencing the serum level. Cytokine. 1994;6(2):181–6.
35 . Adverse reactions during endovascular treatment of aortic aneurysms may be triggered by interleukin 6 release from the thrombotic content. J Vasc Surg. 1998;28(4):664–8.
36 . Tumor necrosis factor-alpha and interleukin-6 release from white blood cells induced by different graft materials in vitro are affected by pentoxifylline and iloprost. J Biomed Mater Res. 1997;36(3):400–6.
37 . Influence of mesh materials on the expression of mediators involved in wound healing. J Investig Surg. 2011;24(2):87–98.
38 Editor’s Choice – Systematic review and meta-analysis of the outcome of treatment for type II endoleak following endovascular aneurysm repair. Eur J Vasc Endovasc Surg. 2018;56(6):794–807.
39 . Management of endoleaks following endovascular aneurysm repair. Seminars in Interventional Radiology. 2009;26(1):33–8.
40 . Clinical significance of type II endoleak after endovascular repair of abdominal aortic aneurysm. Ann Vasc Surg. 2006;20(1):69–74.
41 . Endoleak after endovascular aneurysm repair: Current concepts. J Cardiovasc Surg. 2004;45(4):349–66.
42 An 8-year experience with type II endoleaks: Natural history suggests selective intervention is a safe approach. J Vasc Surg. 2006;44(3):453–9.
43 Risk factors and consequences of persistent type II endoleaks. J Vasc Surg. 2016;63(4):895–901. http://www.ncbi.nlm.nih.gov/pubmed/26796291
44 Incidence, natural course, and outcome of type II endoleaks in infrarenal endovascular aneurysm repair based on the ENGAGE registry data. J Vasc Surg. 2020;71(3):780–9.
45 Ambient particulate matter accelerates coagulation via an IL-6-dependent pathway. J Clin Invest. 2007;117(10):2952–61.
46 Interleukin-6 mediates the platelet abnormalities and thrombogenesis associated with experimental colitis. Am J Pathol. 2013;183(1):173–81.
47 . Platelet activation and platelet-leukocyte aggregation elicited in experimental colitis are mediated by interleukin-6. Inflamm Bowel Dis. 2014;20(2):353–62.
48 . Current evidence on management of aortic stent-graft infection: a systematic review and meta-analysis [Internet]. Ann Vasc Surg. 2018;51:306–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29772328
49 Results from the Multicenter Study on Aortoenteric Fistulization After Stent Grafting of the Abdominal Aorta (MAEFISTO). J Vasc Surg. 2016;64(2):313–320.e1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27289529
50 Preliminary Results from a National Enquiry of Infection in Abdominal Aortic Endovascular Repair (Registry of Infection in EVAR – R.I.EVAR). Ann Vasc Surg. 2016;30:198–204.
51 . Risk factors and treatment outcomes for stent graft infection after endovascular aortic aneurysm repair. J Vasc Surg. 2019;70(1):181–92.
52 Perigraft air, fever, and leukocytosis after endovascular repair of abdominal aortic aneurysms. Am J Surg. 1999;178(3):185–9.
53 Elevated serum interleukin-6 is predictive of coronary artery disease in intermediate risk overweight patients referred for coronary angiography. Diabetol Metab Syndr. 2017;9(1).
54 Interleukin-6 receptor pathways in coronary heart disease: A collaborative meta-analysis of 82 studies. Lancet. 2012;379(9822):1205–13.
55 . Interleukin 6 inhibition and coronary artery disease in a high-risk population: A prospective community-based clinical study. J Am Heart Assoc. 2017;6(3).
56 . Fatigue and interleukin-6 - A multi-faceted relationship. Reumatologia. 2015;53:207–12.
57 . Integrating Interleukin-6 into depression diagnosis and treatment. Neurobiol Stress. 2016;4:15–22.
58 . The Systemic Inflammatory Response Syndrome (SIRS) in acutely hospitalised medical patients: a cohort study. Scand J Trauma Resusc Emerg Med. 2009;17:67.
59 . Glucocorticoid treatment and cardiovascular disease. Heart. 2004;90:829–30.
60 . Systemic glucocorticoid therapy: A review of its metabolic and cardiovascular adverse events. Drugs. 2014;74:1731–45.
61 . Glucocorticoids and cardiovascular risk factors [Internet]. Endocrinol Metab Clin North Am. 2011;40:409–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21565675
62 . Antipyretic therapy: Physiologic rationale, diagnostic implications, and clinical consequences. Arch Int Med. 2000;160(4):449–56.
63 . Procalcitonin for guidance of antibiotic therapy [Internet]. Expert Rev Anti Infect Ther. 2010;8:575–87. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20455686
64 . Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med. 2011;9(1):107.
